A CDK4/6 inhibitor enhances cytotoxicity of paclitaxel in lung adenocarcinoma cells harboring mutant KRAS as well as wild-type KRAS

The KRAS gain-of-function mutation confers intrinsic resistance to targeted anti-cancer drugs and cytotoxic chemotherapeutic agents, ultimately leading to treatment failure. KRAS mutation frequency in lung adenocarcinoma is ~15–30%. Novel therapeutic strategies should be developed to improve clinica...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Xiang-Hua, Cheng, Ying, Shin, Jung-Young, Kim, Jeong-Oh, Oh, Ji-Eun, Kang, Jin-Hyoung
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Landes Bioscience 2013
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3742489/
https://www.ncbi.nlm.nih.gov/pubmed/23792647
http://dx.doi.org/10.4161/cbt.24592

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3742489/
https://www.ncbi.nlm.nih.gov/pubmed/23792647
http://dx.doi.org/10.4161/cbt.24592

Ejemplares similares